Masimo (NASDAQ:MASI) updated its FY 2020
Pre-Market earnings guidance on Tuesday. The company provided earnings per share guidance of 3.56-3.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.56. The company issued revenue guidance of $1.035-1.035 billion, compared to the consensus revenue estimate of $1.04 billion.Masimo also updated its FY 2019
Pre-Market guidance to 3.18 EPS.
Several brokerages have issued reports on MASI. UBS Group raised their price objective on shares of Masimo from $180.00 to $190.00 and gave the stock a buy rating in a research report on Wednesday. ValuEngine cut shares of Masimo from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Piper Sandler restated a buy rating and issued a $175.00 target price on shares of Masimo in a research note on Wednesday. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a research note on Monday, December 16th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $175.00 target price (up previously from $161.00) on shares of Masimo in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $165.07.
Shares of MASI stock traded up $1.33 during mid-day trading on Thursday, hitting $169.45. The stock had a trading volume of 3,289 shares, compared to its average volume of 304,037. Masimo has a fifty-two week low of $115.72 and a fifty-two week high of $167.87. The firm has a market cap of $8.75 billion, a PE ratio of 55.81, a PEG ratio of 2.00 and a beta of 1.13. The company’s 50-day simple moving average is $158.24 and its 200-day simple moving average is $152.15.
In related news, EVP Thomas Samuel Mcclenahan sold 500 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $159.29, for a total value of $79,645.00. Following the completion of the sale, the executive vice president now owns 5,607 shares in the company, valued at $893,139.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sanford Fitch sold 6,500 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $147.08, for a total transaction of $956,020.00. Following the completion of the sale, the director now owns 50,745 shares of the company’s stock, valued at approximately $7,463,574.60. The disclosure for this sale can be found here. Insiders sold 56,000 shares of company stock valued at $8,683,715 in the last quarter. Company insiders own 11.50% of the company’s stock.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: What does an equal weight rating mean?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.